José Esparza

University of Maryland, Baltimore

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Trends

Author Order

Document Type

Co-Authors

Saladin Osmanov

Abbott (United States)

M Gorziglia

Universidad de Los Andes, Chile

Clarissa R. Damaso

Universidade Federal do Rio de Janeiro

Andreas Nitsche

Robert Koch Institute

Ferdinando Liprandi

Instituto Venezolano de Investigaciones Científicas

William L. Heyward

Dynavax Technologies (United States)

Francisco Javier Martín Gil

Clinical Trial Investigators

Ernesto Novo

University of Zulia

Priscilla A. Schaffer

Baylor College of Medicine

Gilberto Vizcaíno

University of Zulia

Cooperative Institutions

National Institutes of Health

Centers for Disease Control and Prevention

National Institute of Allergy and Infectious Diseases

Baylor College of Medicine

Instituto Venezolano de Investigaciones Científicas

Emory University

Harvard University

World Health Organization

University of Washington

Johns Hopkins University

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Field

Composition and Topography of Structural Polypeptides of Bovine Rotavirus

Journal of General Virology (1981)

Ernesto Novo José Esparza

The composition and topography of the structural polypeptides of bovine rotavirus was studied by polyacrylamide gel electrophoresis of radioactively labelled virus grown in LLC-MK2 cells and by lactoperoxidase-catalysed iodination of single- and double- capsid particles. Bovine rotavirus was found to possess at least six structural polypeptides, three of them associated with the inner capsid (p102K, p91K and p45K) and the others with the outer capsid (p84K, p37K and p34K). The most abundant polypeptide of the inner capsid was p45K, which accounted for approx, 80% of the protein mass, followed by p91K (approx, 20% of the protein mass) and p102K (approx. 1% of the protein mass). Polypeptide 45K is not readily available for iodination, indicating that it is partially covered by p91K, which is the most exposed polypeptide of the inner capsid. The number of polypeptide molecules per single capsid particle (calculated on the basis of an RNA content of 16%) was estimated to be approx. 6 molecules of p102K, 140 of p91K and 989 of p45K. The stoichiometry and degree of exposure of outer capsid polypeptides was more difficult to establish, even when it appears that p84K and p34K are the most exposed components.

Rotavirus Infections

10.1099/0022-1317-56-2-325

Cite

Citations (49)

117 30 Years of HIV Vaccine Research

JAIDS Journal of Acquired Immune Deficiency Syndromes (2014)

José Esparza

Soon after HIV was discovered as the cause of AIDS in 1983–1984, there was an expectation that a preventive vaccine would be rapidly developed. The first HIV vaccine paradigm was aimed at inducing neutralizing antibodies, with numerous recombinant envelope proteins tested in clinical trials. It came to an end in 2003, with the negative results from the VaxGen trials in North America and Thailand. The second paradigm aimed at inducing CD8+ T-cell responses, and it led to the development of DNA vaccines and of live-recombinant viral vectors, especially poxviruses and adenoviruses (Ad). The concept was tested in the STEP and Phambili trials, using an Ad5 vector. The trials were stopped in 2007, after an interim review of STEP showed that the vaccine failed to prevent HIV infection or to decrease virus load in vaccinated volunteers who became infected, and even enhanced HIV acquisition in a subpopulation of vaccinated individuals. The current wave of vaccine development is attempting to induce more complex immune responses and exploring novel approaches. The RV 144 trial in Thailand, which assessed the protective efficacy of a prime-boost protocol using a canarypox vectors followed by gp120 boosts, showed 31.2% efficacy in preventing HIV acquisition and presumptive immune correlates have been identified. The field is now exploring new leads that include the rational design of novel immunogens based on epitopes recognized by broadly neutralizing antibodies, live replication-competent vectors and the role of potentially protective non-neutralizing antibodies.

HIV vaccine

AIDS Vaccines

10.1097/01.qai.0000446697.38847.19

Cite

Citations (0)

Cost effectiveness and delivery study for future HIV vaccines

AIDS (2005)

D C Barth-Jones H Cheng Laiyi Kang Patrick Kenya Doreen Awino Odera

Research teams from five countries, Brazil, China, Kenya, Peru and Thailand, have initiated a policy-maker survey on vaccine delivery, cost studies for future HIV vaccination programmes, and associated simulation modeling exercises analysing the relative cost-effectiveness of potential HIV vaccination strategies. The survey assesses challenges and opportunities for future country-level HIV vaccination strategies, providing data on the vaccine characteristics (e.g. vaccine efficacies for susceptibility, infectiousness and disease progression) and vaccination programme strategies to be considered in the cost-effectiveness modeling analyses. The study will provide decision-makers with modeling data on vaccination policy considerations that will assist in developing country-level capacities for future HIV vaccine policy adoption and effective delivery systems, and will help delineate the long-term financial requirements for sustainable HIV vaccination programmes. The WHO-UNAIDS HIV Vaccine Initiative and the collaborating researchers welcome comments or questions from policy makers, health professionals and other stakeholders in the public and private sectors about this effort to help advance policy and capacity related to future potential HIV vaccines.

HIV vaccine

AIDS Vaccines

10.1097/01.aids.0000181014.08127.a7

Cite

Citations (13)

Proposed 'World Health Organization staging system for HIV infection and disease': preliminary testing by an international collaborative cross-sectional study. The WHO International Collaborating Group for the Study of the WHO Staging System.

PubMed (1993)

P. Crocchiolo José Esparza

To evaluate a universally applicable staging system for HIV infection and disease proposed by the Global Programme on AIDS (GPA) of the World Health Organization (WHO). The system consists of both a 'clinical' and a 'laboratory' axis. The 'clinical axis' is represented by a sequential list of clinical conditions believed to have prognostic significance, which subdivides the course of HIV infection into four clinical stages. The 'laboratory axis' subdivides each clinical stage into three strata according to CD4+ cell or total lymphocyte count.International cross-sectional study.Twenty-seven clinical centres in 20 countries.A total of 938 confirmed HIV-positive patients, aged at least 13 years.Presence of the clinical condition belonging to the highest stage and its correlation with recent laboratory data (CD4+ cell counts, total lymphocyte counts, beta 2-microglobulin levels, haemoglobin, haematocrit, erythrocyte sedimentation rate, p24 antigen, p24 antibody and delayed hypersensitivity skin test).There was general agreement between the proposed attribution of clinical conditions and the corresponding laboratory markers. Significant differences were observed between stages 3 and 4 for seven laboratory markers and between stages 2 and 3 for six, but not between stages 1 and 2, for any of the nine laboratory markers.Longitudinal studies are needed to assess whether the proposed system is useful in predicting survival time in patients with HIV disease.

Cross-sectional study

Erythrocyte sedimentation rate

Source

Cite

Citations (51)

Intertypic complementation and recombination between temperature-sensitive mutants of herpes simplex virus types 1 and 2

Virology (1976)

José Esparza Matilda Benyésh-Melnick Priscilla A. Schaffer

HSL and HSV

10.1016/0042-6822(76)90279-8

Cite

Citations (33)

Past, present and future of HIV vaccine trials in developing countries

Vaccine (2002)

José Esparza Saladin Osmanov Claire Pattou-Markovic Coumba Touré Marie-Louise Chang

Pandemic

HIV vaccine

10.1016/s0264-410x(02)00062-2

Cite

Citations (35)

Viruela en Colombia

Luís Carlos Villamil Jiménez Hugo Sotomayor Tribín José Esparza

Los hechos y personajes que lideraron la lucha contra la viruela en Colombia constituyen el aspecto central de este escrito. Temas como el cordón sanitario, el degredo, la variolización y la vacunación brazo a brazo, que se practicó desde 1804 con la llegada de la vacuna al país, son medidas que proceden de España; luego, se habla de la producción de la vacuna colombiana preparada en terneras en el laboratorio central, denominado Parque de Vacunación, donde además de eliminar los efectos adversos del brazo a brazo y se inició el desarrollo de protocolos que permitieron la obtención de una excelente vacuna, que sería utilizada en la prevención, el control y la erradicación temprana de la viruela en nuestro país.

10.19052/9789585486966

Cite

Citations (2)

Viral Gene Functions Expressed and Detected by Temperature-sensitive Mutants of Herpes Simplex Virus

Cold Spring Harbor Symposia on Quantitative Biology (1974)

Matilda Benyésh-Melnick P A Schaffer Richard J. Courtney José Esparza Shoji Kimura

Herpes simplex virus (HSV) is a member of a widespread group of relatively large DNA viruses, some of which have been associated recently with malignancies in man and animals (Klein 1972). Two types of HSV are recognized, type 1 (HSV-1) and type 2 (HSV-2), which share many properties in common but differ in certain biologic, immunologic and biochemical properties (Ejercito et al. 1968; Nahmias et al. 1968; Figueroa and Rawls 1969; Plummer et al. 1970; Roizman et al. 1972). Epidemiologic and virologic evidence has indicated a close association between HSV-2 and cervical cancer (Rawls et al. 1969; Nahmias et al. 1970; Royston and Aurelian 1970; Frenkel et al. 1972). Transformation of cultured mammalian cells has been accomplished with HSV-2 (Duff and Rapp 1971; Kutinova et al. 1973) and with HSV-1 (Munyon et al. 1971; Davidson et al. 1973; Duff and Rapp 1973; Garfinkle and McAuslan 1974).

10.1101/sqb.1974.039.01.086

Cite

Citations (26)

A Head of State Leading by Example

Emerging infectious diseases (2022)

Terence Chorba José Esparza

B efore the introduction of smallpox vaccine, vari- olation was practiced as a preventive measure (i.e., deliberate infection with smallpox to provide immunity), most commonly by inserting or rubbing material from smallpox lesions into the skin of uninfected persons.Most persons thus infected would get a milder case of smallpox as the virus was generally introduced via the skin rather than via the respiratory route, as in the case of natural exposure.

10.3201/eid2810.ac2810

Cite

Citations (0)

Multiplication of Vesicular Stomatitis Virus in the Leafhopper Peregrinus maidis (Ashm.), a Vector of a Plant Rhabdovirus

Journal of General Virology (1976)

Jorge Lastra José Esparza

Vesicular stomatitis virus (VSV) was found to multiply efficiently in whole Peregrinus maidis (Ashm.). the leafhopper vector of maize mosaic virus (MMV), a plant rhabdovirus. Insects were inoculated with VSV by means of a microsyringe, collected at 1-day intervals and tested individually for the presence of virus. Exponential virus multiplication occurred within the first 4 days, reaching titres of 10(6) p.f.u. per insect in days 5 to 10 after inoculation. These observations show that a common host is avialable to study the multiplication of a plant and an animal rhabdovirus.

Vesicular Stomatitis

Pieris brassicae

10.1099/0022-1317-32-1-139

Cite

Citations (24)